Buy Rating for Precision BioSciences Driven by Favorable FDA Guidelines and Promising Data

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences, with a price target of $60.00.

Patrick Trucchio has given his Buy rating due to a combination of factors that align with the recent FDA draft guidances on genetic medicines. These guidances support trial design flexibility, including adaptive and externally controlled trials, which are beneficial for Precision BioSciences’ ARCUS gene editing strategy. The FDA’s recognition of platform technologies and the use of real-world evidence for confirmatory data further strengthens Precision’s position in the market.
Moreover, the FDA’s emphasis on surrogate endpoints and RMAT eligibility could potentially speed up the development timelines for Precision’s programs, such as PBGENE-HBV, if early data continues to show promise. The focus on pediatric inclusion is particularly relevant to Precision’s Duchenne muscular dystrophy program, which targets a rare pediatric disorder. Additionally, positive initial data from a Phase 1/2 trial by Precision’s partner, iECURE, validates the ARCUS platform, reinforcing the Buy rating and a $60 price target for DTIL.